Stanley Laman Group Ltd. Has $7.17 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Stanley Laman Group Ltd. lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 14.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,336 shares of the medical equipment provider's stock after selling 11,011 shares during the period. Lantheus makes up 1.0% of Stanley Laman Group Ltd.'s portfolio, making the stock its 12th biggest position. Stanley Laman Group Ltd. owned approximately 0.09% of Lantheus worth $7,171,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Wellington Management Group LLP lifted its position in shares of Lantheus by 7.9% in the fourth quarter. Wellington Management Group LLP now owns 446,905 shares of the medical equipment provider's stock worth $27,708,000 after purchasing an additional 32,859 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Lantheus by 14.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider's stock worth $596,000 after buying an additional 1,202 shares during the last quarter. NBC Securities Inc. grew its holdings in shares of Lantheus by 28.4% in the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock valued at $53,000 after acquiring an additional 191 shares in the last quarter. Oliver Luxxe Assets LLC acquired a new stake in shares of Lantheus in the first quarter valued at about $547,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Lantheus by 25.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 88,046 shares of the medical equipment provider's stock valued at $5,480,000 after acquiring an additional 18,119 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the topic of several analyst reports. JMP Securities dropped their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Leerink Partners boosted their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Finally, Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Stock Performance

Shares of LNTH stock traded down $1.99 on Wednesday, hitting $110.64. The company's stock had a trading volume of 715,249 shares, compared to its average volume of 967,693. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market capitalization of $7.67 billion, a PE ratio of 16.89 and a beta of 0.50. The stock's 50 day moving average is $106.72 and its 200-day moving average is $92.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the company earned $1.40 EPS. The business's revenue for the quarter was up 22.5% on a year-over-year basis. Equities research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 10,481 shares of Lantheus stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at approximately $43,445,146.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.